Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Keywords: COVID-19; bamlanivimab; outcomes; treatment.
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.